{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T08:57:29Z","timestamp":1785488249723,"version":"3.56.0"},"reference-count":103,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2004,2,1]],"date-time":"2004-02-01T00:00:00Z","timestamp":1075593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2004,2,1]],"date-time":"2004-02-01T00:00:00Z","timestamp":1075593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ajkd.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Kidney Diseases"],"published-print":{"date-parts":[[2004,2]]},"DOI":"10.1053\/j.ajkd.2003.10.013","type":"journal-article","created":{"date-parts":[[2004,1,28]],"date-time":"2004-01-28T12:13:32Z","timestamp":1075292012000},"page":"223-233","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":76,"title":["Apolipoprotein E and renal disease"],"prefix":"10.1053","volume":"43","author":[{"given":"Evagelos","family":"Liberopoulos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kostas","family":"Siamopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moses","family":"Elisaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.ajkd.2003.10.013_BIB1","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1126\/science.3283935","article-title":"Apolipoprotein E","volume":"240","author":"Mahley","year":"1988","journal-title":"Science"},{"key":"10.1053\/j.ajkd.2003.10.013_BIB2","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1097\/00041433-199610000-00007","article-title":"Close encounters with apolipoprotein E receptors","volume":"7","author":"Yamamoto","year":"1996","journal-title":"Curr Opin Lipidol"},{"key":"10.1053\/j.ajkd.2003.10.013_BIB3","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/0002-8703(87)90610-7","article-title":"Apolipoprotein E polymorphism in health and disease","volume":"113","author":"Utermann","year":"1987","journal-title":"Am Heart J"},{"key":"10.1053\/j.ajkd.2003.10.013_BIB4","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1007\/BF00286508","article-title":"Apolipoprotein E phenotypes and hyperlipidemia","volume":"65","author":"Utermann","year":"1984","journal-title":"Hum Genet"},{"key":"10.1053\/j.ajkd.2003.10.013_BIB5","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1172\/JCI113107","article-title":"Intestinal cholesterol absorption efficiency in man is related to apolipoprotein E phenotype","volume":"80","author":"Kesaniemi","year":"1987","journal-title":"J Clin Invest"},{"key":"10.1053\/j.ajkd.2003.10.013_BIB6","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1097\/00041433-199906000-00003","article-title":"Apolipoprotein E","volume":"10","author":"Mahley","year":"1999","journal-title":"Curr Opin Lipidol"},{"key":"10.1053\/j.ajkd.2003.10.013_BIB7","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1152\/physiolgenomics.2000.4.2.101","article-title":"APO E gene and gene-environment effects on plasma lipoprotein-lipid levels","volume":"4","author":"Hagberg","year":"2000","journal-title":"Physiol Genomics"},{"key":"10.1053\/j.ajkd.2003.10.013_BIB8","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1159\/000048256","article-title":"Are the effects of tamoxifen on serum lipid profile modified by apolipoprotein E phenotypes?","volume":"62","author":"Liberopoulos","year":"2002","journal-title":"Oncology"},{"key":"10.1053\/j.ajkd.2003.10.013_BIB9","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0009-9120(01)00197-7","article-title":"The effect of tamoxifen therapy on serum apolipoprotein A-I level is modified by the apolipoprotein E phenotype","volume":"34","author":"Liberopoulos","year":"2001","journal-title":"Clin Biochem"},{"key":"10.1053\/j.ajkd.2003.10.013_BIB10","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1038\/269604a0","article-title":"Polymorphism of apo E and occurrence of dysbetalipoproteinemia in man","volume":"269","author":"Utermann","year":"1977","journal-title":"Nature"},{"key":"10.1053\/j.ajkd.2003.10.013_BIB11","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1001\/jama.1994.03520210050031","article-title":"Apolipoprotein E alleles, dyslipidemia, and coronary heart disease. The Framingham Offspring Study","volume":"272","author":"Wilson","year":"1994","journal-title":"JAMA"},{"key":"10.1053\/j.ajkd.2003.10.013_BIB12","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1212\/WNL.53.6.1308","article-title":"APOE genotype as a risk factor for ischemic cerebrovascular disease. A meta-analysis","volume":"53","author":"McCarron","year":"1999","journal-title":"Neurology"},{"key":"10.1053\/j.ajkd.2003.10.013_BIB13","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1097\/00041433-200006000-00004","article-title":"Apolipoprotein E and atherosclerosis","volume":"11","author":"Curtiss","year":"2000","journal-title":"Curr Opin Lipidol"},{"key":"10.1053\/j.ajkd.2003.10.013_BIB14","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/0033-0620(80)90027-4","article-title":"Cardiovascular disease in patients on hemodialytic therapy","volume":"22","author":"Scharf","year":"1980","journal-title":"Prog Cardiovasc Dis"},{"key":"10.1053\/j.ajkd.2003.10.013_BIB15","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1177\/089686089701700302","article-title":"Is CAPD atherogenic?","volume":"17","author":"Siamopoulos","year":"1997","journal-title":"Perit Dial Int"},{"key":"10.1053\/j.ajkd.2003.10.013_BIB16","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/S0009-9120(01)00274-0","article-title":"Evaluation of five methods for determining low-density lipoprotein cholesterol (LDL-C) in hemodialysis patients","volume":"34","author":"Bairaktari","year":"2001","journal-title":"Clin Biochem"},{"key":"10.1053\/j.ajkd.2003.10.013_BIB17","first-page":"331","article-title":"Dyslipidaemia in patients with renal diseases","volume":"7","author":"Elisaf","year":"1996","journal-title":"J Drug Dev Clin Pract"},{"key":"10.1053\/j.ajkd.2003.10.013_BIB18","first-page":"642","article-title":"Atherogenic lipid and lipoprotein parameters in hemodialysis patients","volume":"24","author":"Elisaf","year":"1995","journal-title":"Dial Transplant"},{"key":"10.1053\/j.ajkd.2003.10.013_BIB19","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1177\/089686089501500410","article-title":"Lipid parameters including lipoprotein(a) in patients undergoing CAPD and hemodialysis","volume":"15","author":"Siamopoulos","year":"1995","journal-title":"Perit Dial Int"},{"key":"10.1053\/j.ajkd.2003.10.013_BIB20","doi-asserted-by":"crossref","first-page":"101","DOI":"10.3109\/00365599309180423","article-title":"Lipid abnormalities in chronic uremic patients. Response to treatment with gemfibrozil","volume":"27","author":"Elisaf","year":"1993","journal-title":"Scand J Urol Nephrol"},{"key":"10.1053\/j.ajkd.2003.10.013_BIB21","first-page":"198","article-title":"Lipoprotein(a) levels in diabetics on chronic hemodialysis","volume":"8","author":"Elisaf","year":"1995","journal-title":"J Nephrol"},{"key":"10.1053\/j.ajkd.2003.10.013_BIB22","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1159\/000045073","article-title":"Serum Lp(a) levels in patients with moderate renal failure","volume":"79","author":"Bairaktari","year":"1998","journal-title":"Nephron"},{"key":"10.1053\/j.ajkd.2003.10.013_BIB23","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1016\/S0272-6386(99)70147-2","article-title":"Apolipoprotein (a) phenotypes and lipoprotein(a) concentrations in patients with renal failure","volume":"33","author":"Milionis","year":"1999","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ajkd.2003.10.013_BIB24","first-page":"289","article-title":"Increased lipoprotein(a) levels in patients with proteinuria","volume":"6","author":"Elisaf","year":"1996","journal-title":"Cardiovasc Risk Factors"},{"key":"10.1053\/j.ajkd.2003.10.013_BIB25","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/0021-9150(91)90111-F","article-title":"Apolipoprotein E polymorphism affects plasma levels of lipoprotein(a)","volume":"90","author":"De Knijff","year":"1991","journal-title":"Atherosclerosis"},{"key":"10.1053\/j.ajkd.2003.10.013_BIB26","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1046\/j.1523-1755.1999.00788.x","article-title":"Plasma and Lp(a)-associated PAF-acetylhydrolase activity in uremic patients undergoing different dialysis procedures","volume":"56","author":"Milionis","year":"1999","journal-title":"Kidney Int"},{"key":"10.1053\/j.ajkd.2003.10.013_BIB27","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1046\/j.1523-1755.63.s84.22.x","article-title":"Update on C-reactive protein as a risk marker in cardiovascular disease","volume":"84","author":"Koenig","year":"2003","journal-title":"Kidney Int Suppl"},{"key":"10.1053\/j.ajkd.2003.10.013_BIB28","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1159\/000167599","article-title":"Lipids and progressive glomerulosclerosis","volume":"8","author":"Keane","year":"1988","journal-title":"Am J Nephrol"},{"key":"10.1053\/j.ajkd.2003.10.013_BIB29","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1053\/ajkd.2000.17682","article-title":"Effect of apolipoprotein E polymorphism on serum lipid, lipoproteins, and atherosclerosis in hemodialysis patients","volume":"36","author":"Guz","year":"2000","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ajkd.2003.10.013_BIB30","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/BF00197265","article-title":"Apolipoprotein E phenotypes and hyperlipidemia in patients under maintenance hemodialysis","volume":"88","author":"Feussner","year":"1992","journal-title":"Hum Genet"},{"key":"10.1053\/j.ajkd.2003.10.013_BIB31","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1093\/ndt\/12.1.141","article-title":"Influence of variation at the apolipoprotein E locus on lipid and lipoprotein levels in CAPD patients","volume":"12","author":"Eggertsen","year":"1997","journal-title":"Nephrol Dial Transplant"},{"key":"10.1053\/j.ajkd.2003.10.013_BIB32","doi-asserted-by":"crossref","first-page":"S245","DOI":"10.1046\/j.1523-1755.1999.07165.x","article-title":"Apolipoprotein E phenotypes in hemodialysis patients","volume":"71","author":"Imura","year":"1999","journal-title":"Kidney Int Suppl"},{"key":"10.1053\/j.ajkd.2003.10.013_BIB33","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1046\/j.1523-1755.1999.07107.x","article-title":"Apolipoprotein E polymorphism and renal disease","volume":"71","author":"Oda","year":"1999","journal-title":"Kidney Int Suppl"},{"key":"10.1053\/j.ajkd.2003.10.013_BIB34","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1093\/clinchem\/40.5.849","article-title":"Apolipoprotein E phenotype and hyperlipoproteinemia in nephrotic syndrome","volume":"40","author":"Lerique","year":"1994","journal-title":"Clin Chem"},{"key":"10.1053\/j.ajkd.2003.10.013_BIB35","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1159\/000045469","article-title":"Increased prevalence of apolipoprotein E3\/E4 genotype among Swedish renal transplant recipients","volume":"83","author":"Roussos","year":"1999","journal-title":"Nephron"},{"key":"10.1053\/j.ajkd.2003.10.013_BIB36","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1159\/000045517","article-title":"Apolipoprotein E polymorphism in IgA nephropathy","volume":"83","author":"Yorioka","year":"1999","journal-title":"Nephron"},{"key":"10.1053\/j.ajkd.2003.10.013_BIB37","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s004670050599","article-title":"Apolipoprotein E \u025b4 allele and nephrotic glomerular diseases in children","volume":"13","author":"Asami","year":"1999","journal-title":"Pediatr Nephrol"},{"key":"10.1053\/j.ajkd.2003.10.013_BIB38","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1056\/NEJM198208053070601","article-title":"Increased lipoprotein-remnant formation in chronic renal failure","volume":"307","author":"Nestel","year":"1982","journal-title":"N Engl J Med"},{"key":"10.1053\/j.ajkd.2003.10.013_BIB39","first-page":"141","article-title":"The influence of apoprotein \u025b2 homozygosity on nephrotic hyperlipidemia","volume":"48","author":"Joven","year":"1997","journal-title":"Clin Nephrol"},{"key":"10.1053\/j.ajkd.2003.10.013_BIB40","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1681\/ASN.V641170","article-title":"Atypical hyperlipidemia and nephropathy associated with apolipoprotein E homozygosity","volume":"6","author":"Ellis","year":"1995","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/j.ajkd.2003.10.013_BIB41","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1016\/0026-0495(90)90094-S","article-title":"Type III hyperlipoproteinemia in a child with hemolytic uremic syndrome","volume":"39","author":"Feussner","year":"1990","journal-title":"Metabolism"},{"key":"10.1053\/j.ajkd.2003.10.013_BIB42","first-page":"51","article-title":"Type 3 hyperlipoproteinemia with mesangial foam cells in renal glomeruli","volume":"98","author":"Amatruda","year":"1976","journal-title":"Arch Pathol"},{"key":"10.1053\/j.ajkd.2003.10.013_BIB43","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1046\/j.1365-2796.1996.501855000.x","article-title":"Glomerular lipid deposition and proteinuria in a patient with familial dysbetalipoproteinaemia","volume":"240","author":"Balson","year":"1996","journal-title":"J Intern Med"},{"key":"10.1053\/j.ajkd.2003.10.013_BIB44","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/0021-9150(90)90025-E","article-title":"Effects of plasmapheresis on familial type III hyperlipoproteinemia associated with glomerular lipidosis, nephrotic syndrome and diabetes mellitus","volume":"80","author":"Suzaki","year":"1990","journal-title":"Atherosclerosis"},{"key":"10.1053\/j.ajkd.2003.10.013_BIB45","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1046\/j.1523-1755.2001.0590051911.x","article-title":"Novel glomerular lipoprotein deposits associated with apolipoprotein E2 homozygosity","volume":"59","author":"Sakatsume","year":"2001","journal-title":"Kidney Int"},{"key":"10.1053\/j.ajkd.2003.10.013_BIB46","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1159\/000059820","article-title":"Apolipoprotein E phenotype and renal disease","volume":"120","author":"Oda","year":"1997","journal-title":"Contrib Nephrol"},{"key":"10.1053\/j.ajkd.2003.10.013_BIB47","first-page":"243","article-title":"Influence of apolipoprotein E genotype on lipid and lipoprotein levels in continuous ambulatory peritoneal dialysis patients","volume":"15","author":"Choi","year":"1999","journal-title":"Adv Perit Dial"},{"key":"10.1053\/j.ajkd.2003.10.013_BIB48","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1093\/ndt\/12.4.691","article-title":"Preliminary evidence for a role of apolipoprotein E alleles in identifying haemodialysis patients at high vascular risk","volume":"12","author":"Olmer","year":"1997","journal-title":"Nephrol Dial Transplant"},{"key":"10.1053\/j.ajkd.2003.10.013_BIB49","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1093\/ndt\/12.9.1916","article-title":"Prevalence of apolipoprotein E genotypes in ischaemic cerebrovascular disease in end-stage renal disease patients","volume":"12","author":"Lim","year":"1997","journal-title":"Nephrol Dial Transplant"},{"key":"10.1053\/j.ajkd.2003.10.013_BIB50","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1034\/j.1600-6143.2002.20409.x","article-title":"Apolipoprotein C-III and E polymorphisms and cardiovascular syndrome, hyperlipidemia, and insulin resistance in renal transplantation","volume":"2","author":"Rodrigo","year":"2002","journal-title":"Am J Transplant"},{"key":"10.1053\/j.ajkd.2003.10.013_BIB51","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1136\/bmj.313.7060.779","article-title":"Predictors of mortality in insulin dependent diabetes mellitus","volume":"313","author":"Rossing","year":"1996","journal-title":"BMJ"},{"key":"10.1053\/j.ajkd.2003.10.013_BIB52","series-title":"2001 Annual Data Report","year":"2001"},{"key":"10.1053\/j.ajkd.2003.10.013_BIB53","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1038\/ki.1992.112","article-title":"Is diabetic nephropathy an inherited complication?","volume":"41","author":"Borch-Johnsen","year":"1992","journal-title":"Kidney Int"},{"key":"10.1053\/j.ajkd.2003.10.013_BIB54","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.2337\/diabetes.49.12.2190","article-title":"APOE polymorphisms and the development of diabetic nephropathy in type 1 diabetes","volume":"49","author":"Araki","year":"2000","journal-title":"Diabetes"},{"key":"10.1053\/j.ajkd.2003.10.013_BIB55","doi-asserted-by":"crossref","first-page":"278","DOI":"10.2337\/diab.47.2.278","article-title":"Association of apolipoprotein \u025b2 allele with diabetic nephropathy in Caucasian subjects with IDDM","volume":"47","author":"Chowdhury","year":"1998","journal-title":"Diabetes"},{"key":"10.1053\/j.ajkd.2003.10.013_BIB56","doi-asserted-by":"crossref","first-page":"994","DOI":"10.2337\/diacare.21.6.994","article-title":"Apolipoprotein E polymorphism and renal function in German type 1 and type 2 diabetic patients","volume":"21","author":"Werle","year":"1998","journal-title":"Diabetes Care"},{"key":"10.1053\/j.ajkd.2003.10.013_BIB57","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1046\/j.1523-1755.2002.00507.x","article-title":"Nephropathy in type 1 diabetes","volume":"62","author":"Orchard","year":"2002","journal-title":"Kidney Int"},{"key":"10.1053\/j.ajkd.2003.10.013_BIB58","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1681\/ASN.V771075","article-title":"Apolipoprotein E genotypes and risk of diabetic nephropathy","volume":"7","author":"Onuma","year":"1996","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/j.ajkd.2003.10.013_BIB59","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1093\/ndt\/15.12.1971","article-title":"Lack of relationship in long-term type 1 diabetic patients between diabetic nephropathy and polymorphisms in apolipoprotein epsilon, lipoprotein lipase and cholesteryl ester transfer protein (GENEDIAB Study)","volume":"15","author":"Hadjadj","year":"2000","journal-title":"Nephrol Dial Transplant"},{"key":"10.1053\/j.ajkd.2003.10.013_BIB60","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1093\/ndt\/15.5.625","article-title":"Plasminogen activator inhibitor-1 and apolipoprotein E gene polymorphisms and diabetic angiopathy","volume":"15","author":"Tarnow","year":"2000","journal-title":"Nephrol Dial Transplant"},{"key":"10.1053\/j.ajkd.2003.10.013_BIB61","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1007\/s001250051538","article-title":"Differences in HDL-cholesterol","volume":"43","author":"Soedamah-Muthu","year":"2000","journal-title":"Diabetologia"},{"key":"10.1053\/j.ajkd.2003.10.013_BIB62","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/ng0194-29","article-title":"Genetic associations with human longevity at the APOE and ACE loci","volume":"6","author":"Schachter","year":"1994","journal-title":"Nat Genet"},{"key":"10.1053\/j.ajkd.2003.10.013_BIB63","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1053\/ajkd.2002.34502","article-title":"Apolipoprotein E genetic polymorphism, remnant lipoproteins, and nephropathy in type 2 diabetic patients","volume":"40","author":"Eto","year":"2002","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ajkd.2003.10.013_BIB64","first-page":"368","article-title":"Higher frequency of apolipoprotein E2 allele in type 2 diabetic patients with nephropathy in Taiwan","volume":"15","author":"Hsieh","year":"2002","journal-title":"J Nephrol"},{"key":"10.1053\/j.ajkd.2003.10.013_BIB65","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1111\/j.1399-0004.1995.tb04111.x","article-title":"Increased frequency of apolipoprotein \u025b2 allele in non-insulin dependent diabetic (NIDDM) patients with nephropathy","volume":"48","author":"Eto","year":"1995","journal-title":"Clin Genet"},{"key":"10.1053\/j.ajkd.2003.10.013_BIB66","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1093\/ndt\/14.9.2144","article-title":"Association between apolipoprotein E polymorphism and macroalbuminuria in patients with non-insulin dependent diabetes mellitus","volume":"14","author":"Ha","year":"1999","journal-title":"Nephrol Dial Transplant"},{"key":"10.1053\/j.ajkd.2003.10.013_BIB67","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1093\/ndt\/13.1.72","article-title":"ApoE polymorphism and albuminuria in diabetes mellitus","volume":"13","author":"Boize","year":"1998","journal-title":"Nephrol Dial Transplant"},{"key":"10.1053\/j.ajkd.2003.10.013_BIB68","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1053\/ajkd.1998.v31.pm9531184","article-title":"Apolipoprotein E4 reduces risk of diabetic nephropathy in patients with NIDDM","volume":"31","author":"Kimura","year":"1998","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ajkd.2003.10.013_BIB69","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1007\/BF02256061","article-title":"Apolipoprotein E gene polymorphism, hypercholesterolemia and glomerular filtration rate in type 2 diabetic subjects","volume":"10","author":"Lehtinen","year":"2003","journal-title":"J Biomed Sci"},{"key":"10.1053\/j.ajkd.2003.10.013_BIB70","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/S0046-8177(87)80238-1","article-title":"Renal lipidoses","volume":"18","author":"Farrangiana","year":"1987","journal-title":"Hum Pathol"},{"key":"10.1053\/j.ajkd.2003.10.013_BIB71","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/S0272-6386(12)80649-4","article-title":"Abnormal lipoprotein and apolipoprotein pattern in lipoprotein glomerulopathy","volume":"18","author":"Oikawa","year":"1991","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ajkd.2003.10.013_BIB72","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1159\/000168591","article-title":"Lipoprotein glomerulopathy","volume":"13","author":"Siato","year":"1993","journal-title":"Am J Nephrol"},{"key":"10.1053\/j.ajkd.2003.10.013_BIB73","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s004670050264","article-title":"Lipoprotein glomerulopathy","volume":"11","author":"Maruyama","year":"1997","journal-title":"Pediatr Nephrol"},{"key":"10.1053\/j.ajkd.2003.10.013_BIB74","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/S0272-6386(12)81066-3","article-title":"Lipoprotein glomerulopathy","volume":"24","author":"Zhang","year":"1994","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ajkd.2003.10.013_BIB75","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S1050-1738(01)00148-7","article-title":"Etiologic significance of apolipoprotein E mutations in lipoprotein glomerulopathy","volume":"12","author":"Saito","year":"2002","journal-title":"Trend Cardiovasc Med"},{"key":"10.1053\/j.ajkd.2003.10.013_BIB76","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.1046\/j.1523-1755.1999.07110.x","article-title":"Lipoprotein glomerulopathy","volume":"71","author":"Saito","year":"1999","journal-title":"Kidney Int Suppl"},{"key":"10.1053\/j.ajkd.2003.10.013_BIB77","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1159\/000045511","article-title":"Lipoprotein glomerulopathy","volume":"83","author":"Saito","year":"1999","journal-title":"Nephron"},{"key":"10.1053\/j.ajkd.2003.10.013_BIB78","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1159\/000059821","article-title":"Lipoprotein glomerulopathy and its pathogenesis","volume":"120","author":"Saito","year":"1997","journal-title":"Contrib Nephrol"},{"key":"10.1053\/j.ajkd.2003.10.013_BIB79","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1681\/ASN.V85840","article-title":"Lipoprotein glomerulopathy","volume":"8","author":"Karet","year":"1997","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/j.ajkd.2003.10.013_BIB80","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1681\/ASN.V85820","article-title":"Apolipoprotein E Sendai (Arginine 145\u2192proline)","volume":"8","author":"Oikawa","year":"1997","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/j.ajkd.2003.10.013_BIB81","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1046\/j.1523-1755.1999.00677.x","article-title":"A novel 18-amino acid deletion in apolipoprotein E associated with lipoprotein glomerulopathy","volume":"56","author":"Ando","year":"1999","journal-title":"Kidney Int"},{"key":"10.1053\/j.ajkd.2003.10.013_BIB82","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1159\/000045513","article-title":"Association of a novel 3-amino acid deletion of apolipoprotein E (Apo E Tokyo) with lipoprotein glomerulopathy","volume":"83","author":"Konishi","year":"1999","journal-title":"Nephron"},{"key":"10.1053\/j.ajkd.2003.10.013_BIB83","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1046\/j.1523-1755.1999.00572.x","article-title":"A novel apolipoprotein E mutation, E2 (Arg25Cys), in lipoprotein glomerulopathy","volume":"56","author":"Matsunaga","year":"1999","journal-title":"Kidney Int"},{"key":"10.1053\/j.ajkd.2003.10.013_BIB84","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s004670050032","article-title":"A new variant of apolipoprotein E (apo E Maebashi) in lipoprotein glomerulopathy","volume":"14","author":"Ogawa","year":"2000","journal-title":"Pediatr Nephrol"},{"key":"10.1053\/j.ajkd.2003.10.013_BIB85","doi-asserted-by":"crossref","first-page":"31269","DOI":"10.1074\/jbc.M005906200","article-title":"Virus-mediated transduction of apolipoprotein E (ApoE)-Sendai develops lipoprotein glomerulopathy in ApoE-deficient mice","volume":"275","author":"Ishigaki","year":"2000","journal-title":"J Biol Chem"},{"key":"10.1053\/j.ajkd.2003.10.013_BIB86","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1681\/ASN.V123524","article-title":"Diminished LDL receptor and high heparin binding of apolipoprotein E2 Sendai associated with lipoprotein glomerulopathy","volume":"12","author":"Hoffmann","year":"2001","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/j.ajkd.2003.10.013_BIB87","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1053\/meta.2002.29990","article-title":"Interaction of endothelial cells and triglyceride-rich lipoproteins with apolipoprotein E (Arg\u2192Cys) from a patient with lipoprotein glomerulopathy","volume":"51","author":"Murano","year":"2002","journal-title":"Metabolism"},{"key":"10.1053\/j.ajkd.2003.10.013_BIB88","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1053\/ajkd.2003.50016","article-title":"Resolution of typical lipoprotein glomerulopathy by intensive lipid-lowering therapy","volume":"41","author":"Ieiri","year":"2003","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ajkd.2003.10.013_BIB89","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s00467-001-0802-1","article-title":"Apolipoprotein E polymorphism in childhood nephrotic syndrome","volume":"17","author":"Attila","year":"2002","journal-title":"Pediatr Nephrol"},{"key":"10.1053\/j.ajkd.2003.10.013_BIB90","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1007\/s002239900430","article-title":"Bone fracture history and prospective bone fracture risk of hemodialysis patients are related to apolipoprotein E genotype","volume":"62","author":"Kohlmeier","year":"1998","journal-title":"Calcif Tissue Int"},{"key":"10.1053\/j.ajkd.2003.10.013_BIB91","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1093\/ajcn\/58.2.204","article-title":"Phylloquinone transport and its influence on \u03b3-carboxyglutamate residues of osteocalcin in patients on maintenance hemodialysis","volume":"58","author":"Saupe","year":"1993","journal-title":"Am J Clin Nutr"},{"key":"10.1053\/j.ajkd.2003.10.013_BIB92","first-page":"S75","article-title":"Apolipoprotein E and alpha 1-antichymotrypsin in dialysis-related amyloidosis","volume":"62","author":"Gejyo","year":"1997","journal-title":"Kidney Int Suppl"},{"key":"10.1053\/j.ajkd.2003.10.013_BIB93","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1097\/00000542-200008000-00008","article-title":"Preliminary report on the association of apolipoprotein E polymorphisms, with postoperative peak serum creatinine concentrations in cardiac surgical patients","volume":"93","author":"Chew","year":"2000","journal-title":"Anesthesiology"},{"key":"10.1053\/j.ajkd.2003.10.013_BIB94","doi-asserted-by":"crossref","first-page":"49142","DOI":"10.1074\/jbc.M104879200","article-title":"A protective role for kidney apolipoprotein E. Regulation of mesangial cell proliferation and matrix expansion","volume":"276","author":"Chen","year":"2001","journal-title":"J Biol Chem"},{"key":"10.1053\/j.ajkd.2003.10.013_BIB95","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1097\/01.LAB.0000022222.03120.D4","article-title":"Renal injury in apolipoprotein E-deficient mice","volume":"82","author":"Wen","year":"2002","journal-title":"Lab Invest"},{"key":"10.1053\/j.ajkd.2003.10.013_BIB96","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1161\/01.ATV.0000051404.84665.49","article-title":"Fluvastatin prevents renal dysfunction and vascular NO deficit in apolipoprotein E-deficient mice","volume":"23","author":"Gervais","year":"2003","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1053\/j.ajkd.2003.10.013_BIB97","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1093\/ndt\/17.12.2099","article-title":"Mesangial expansion associated with glomerular endothelial cell activation and macrophage recruitment is developing in hyperlipidaemic apoE null mice","volume":"17","author":"Bruneval","year":"2002","journal-title":"Nephrol Dial Transplant"},{"key":"10.1053\/j.ajkd.2003.10.013_BIB98","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1073\/pnas.80.1.283","article-title":"Apolipoprotein E synthesis in human kidney, adrenal gland, and liver","volume":"80","author":"Blue","year":"1983","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1053\/j.ajkd.2003.10.013_BIB99","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1093\/clinchem\/37.3.387","article-title":"Abnormal concentrations of CII, CIII, and E apolipoproteins among apolipoprotein B-containing, B-free, and A-I-containing lipoprotein particles in hemodialysis patients","volume":"37","author":"Alsayed","year":"1991","journal-title":"Clin Chem"},{"key":"10.1053\/j.ajkd.2003.10.013_BIB100","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1159\/000169011","article-title":"Apolipoprotein AI and apolipoprotein B containing particle analysis in normolipidemic hemodialyzed patients","volume":"16","author":"Kandoussi","year":"1996","journal-title":"Am J Nephrol"},{"key":"10.1053\/j.ajkd.2003.10.013_BIB101","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1038\/ki.1993.129","article-title":"Apolipoproteins and lipoprotein receptors in glomeruli in human kidney diseases","volume":"43","author":"Takemura","year":"1993","journal-title":"Kidney Int"},{"key":"10.1053\/j.ajkd.2003.10.013_BIB102","first-page":"127","article-title":"Immunohistological localization of apolipoproteins in the glomeruli in renal disease","volume":"36","author":"Sato","year":"1991","journal-title":"Clin Nephrol"},{"key":"10.1053\/j.ajkd.2003.10.013_BIB103","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1038\/ki.1990.135","article-title":"Receptor mediated uptake of apoB and apoE rich lipoproteins by human glomerular epithelial cells","volume":"37","author":"Grone","year":"1990","journal-title":"Kidney Int"}],"container-title":["American Journal of Kidney Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638603013702?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638603013702?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T01:23:01Z","timestamp":1759454581000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272638603013702"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,2]]},"references-count":103,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2004,2]]}},"alternative-id":["S0272638603013702"],"URL":"https:\/\/doi.org\/10.1053\/j.ajkd.2003.10.013","relation":{},"ISSN":["0272-6386"],"issn-type":[{"value":"0272-6386","type":"print"}],"subject":[],"published":{"date-parts":[[2004,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Apolipoprotein E and renal disease","name":"articletitle","label":"Article Title"},{"value":"American Journal of Kidney Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.ajkd.2003.10.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2004 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}